Upadacitinib(Rinvoq)

Upadacitinib is a prescription drug targeting Janus kinases (JAKs). Its indication was expanded and approved in the European Union and Japan in August 2021. It should be used strictly under medical supervision.

Target of Action

Janus kinase (JAK).

Dosage and Administration

Route and frequency of administration for Upadacitinib: 15 mg, once daily.

The dosage of Upadacitinib should be adjusted according to the patient’s actual condition. For specific adjustments, consult a doctor and strictly follow medical advice.

Recommended Reading: Dosage and Administration of Upadacitinib

Side Effects

Common side effects: bronchitis, nausea, cough, etc.

Serious side effects: severe infections, allergic reactions, etc.

Reference Article: Side Effects of Upadacitinib

Use in Special Populations

Pregnancy: Based on animal studies, Upadacitinib may harm your unborn baby. Your doctor will test for pregnancy before you start taking Upadacitinib. Effective contraception must be used during treatment and for 4 weeks after the last dose to prevent pregnancy.

Lactation: If you are breastfeeding or planning to breastfeed. Upadacitinib may pass into breast milk. Do not breastfeed during treatment and for 6 days after the last dose.

Daily Precautions

1. Avoid eating or drinking grapefruit-containing foods or beverages during treatment, as this may increase the risk of side effects.

2. If you have any symptoms of infection, inform your doctor immediately. Upadacitinib may make you more susceptible to infections or worsen any existing infections.

3. Some patients taking Upadacitinib may see medication residues (intact tablets or tablet fragments) in feces. If this occurs, contact your doctor.

from FDA，2023.04